<DOC>
	<DOCNO>NCT03053219</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy male Patients With Advanced NSCLC participant [ 14C ] AC0010 ADME ( absorption , distribution , metabolism excretion ) trial subsequent receive AC0010 treatment</brief_summary>
	<brief_title>Preliminary Evaluation Safety Efficacy Patients Who Participant 14C AC0010 Trail Subsequent Receiving AC0010 Treatment</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>sign date informed consent histologically cytologically confirm diagnosis local advance recurrent NSCLC fail treatment EGFRTKI harbor T790M mutation male , Age 18~ 65 , body mass index ( BMI ) ≥19 kg/m2 Eastern Cooperative Oncology Group performance status ( ECOG PS ) :01 , Life expectancy 3 month main organ function normal , laboratory value list : blood test without blood transfusion within 14 day 1 . Haemoglobin &gt; 100 g/L 2 . Absolute neutrophil count ≥2.0x109/L WBC ≥3.5 x109/L 3 . Platelet count ≥ 80x109/L 4 . Total bilirubin ≤1.5xULN 5 . Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤ 2.5 time upper limit normal ( ULN ) 6 . BUN≤1.5xULN 7 . Serum creatinine ≤1.5xULN creatinine clearance ratio ≥60 mL/min Any prior treatment ( chemotherapy , radiotherapy surgery ) must complete 4 week ( target therapy 2 week ) screening ; Patients must recover toxicity relate prior anticancer therapy grade ≤ 1 ( CTCAE v 4.03 ) International normalize ratio ( INR ) ≤ 1.5 Patients partner willing use method contraception total abstinence start dose 6 month discontinue study treatment Prior treat AC0010 allergic drug formulation ingredient Patients receive antitumor therapy Impairment GI disease , renal disorder liver disease may significantly alter absorption metabolic AC0010 ( e.g. , Unable swallow , liver , kidney gastrointestinal partial resection , chronic diarrhea intestinal obstruction ) HCVAb positive , active hepatitis B ( exclude HBV carrier ) , Hepatitis virus marker positive receive antivirus drug Meningeal metastasis ; brain metastasis whole brain radiotherapy ; prior receive hormone mannitol brain metastasis Previous EGFRTKI treatment relate Interstitial lung disease history Known human immunodeficiency virus infection ( HIV ) , acquire congenital immunodeficiency disease , history organ transplantation Any severe / uncontrolled active infection Patients receive concomitant immunosuppressive agent highdose corticosteroid Any severe / uncontrolled medical condition Patients treat drug recognize inhibitor inducer liver isoenzyme last 4 week prior registration current study Within 3 day prior treatment take dragon fruit , pomelo , grapefruit , orange , mango fruit may affect drug metabolize enzyme juice Within 2 day prior treatment take coffee , tea , cola , chocolate , caffeine containing beverage , alcoholic beverage / alcoholic product Major surgery , incisional biopsy traumatic injury ; Within 4 week prior screen patient bleed ≥ grade 3 , nonhealing wound , sever ulcer bone fracture Patients receive high dose irradiation treatment 14Clabeled drug within 1 year Known history alcoholism drug abuse Nicotine urine drug test positive Participate clinical trial within 4 week prior screen Investigator judgment patient unsuitable participate study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>